NanoViricides is progressing its measles drug development program with a promising broad-spectrum antiviral candidate, NV-387, as concerns grow about potential measles resurgence in the United States. The drug candidate has completed Phase I trials without adverse events and demonstrated strong antiviral efficacy across multiple viruses that utilize the HSPG infection pathway.
With vaccination rates declining, the potential for measles to become endemic has increased, underscoring the importance of developing effective treatment options. NV-387 has already shown success against related viruses like respiratory syncytial virus (RSV) in animal models, providing encouraging preliminary data for its potential effectiveness.
The company is preparing to conduct an animal study in humanized mice to further evaluate NV-387's therapeutic potential. This research could represent a significant advancement in antiviral treatment, particularly for viruses that share similar infection mechanisms.
NanoViricides is targeting multiple viral infections with this drug candidate, including respiratory viral infections, COVID-19, and potential future outbreaks. The broad-spectrum nature of NV-387 suggests it could become a versatile tool in managing emerging viral threats.
